Vicore Pharma Holding AB
VCREHealthcare|Biotechnology|Sweden
$14.01
-0.22 (-1.57%)
Tangible Book
$3.86
Upcoming Data Readouts (1)
May 2027
Est. completion
P2Idiopathic Pulmonary Fibrosis (IPF)
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686n=378